eXoZymes Achieves Near-Perfect Efficiency in Major Manufacturing Scale-Up
New York, Wednesday, 18 March 2026.
eXoZymes successfully scaled its AI-enhanced enzyme technology 100-fold today, achieving a stunning 99% conversion rate. This milestone proves commercial viability, paving the way for industrial-scale biological production.
Defying the Odds of Biological Scale-Up
On March 18, 2026, publicly traded biotech firm eXoZymes Inc. (NASDAQ:EXOZ) announced a major breakthrough in its manufacturing capabilities [1]. In collaboration with Cayman Chemical, the company successfully advanced its biomanufacturing protocol from a standard 1-liter setup to a 100-liter pilot run [1]. This represents a 9900% increase in production volume [1]. Scaling up biological processes is notoriously difficult; as Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical, noted, a common hurdle in cell-based enzymatic biocatalysis is a significant drop in efficacy during scale-up [1]. Moving up orders of magnitude typically alters a process so fundamentally that it must be treated as an entirely new operation [1].
Mitigating Execution Risk Through External Validation
The success of this pilot run serves as a critical external validation for eXoZymes’ cell-free platform [1]. Founded in 2019, eXoZymes has focused on developing a biomanufacturing platform utilizing AI-enhanced enzymes, known as exozymes, to convert abundant feedstock into valuable nutraceuticals [1]. According to Damien Perriman, Chief Commercial Officer at eXoZymes, reaching this pilot scale in under a year highlights the company’s ability to advance its research and development at a disruptive pace [1].
Paving the Way for Commercial Partnerships
Armed with the successful production of over 500 grams of pharma-grade NCT, eXoZymes is now accelerating its commercialization strategy [1]. As of March 18, 2026, the company is actively engaging with prospective partners who are interested in evaluating the technology, developing formulations, and conducting application-specific testing [1]. eXoZymes plans to ship these newly produced formulations directly to partners for product validation [1].